Life Science Today
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs.
Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
The Niche Episode 070 – Incyte, Cue Health, Velocity, PROCEPT, Catalent
Double approval, double acquisition, $200M for tests, $200M for prostate robots, $450M for $1B worth of gummies
Find out more at
https://thenichepod.com
Story References
https://tinyurl.com/Niche-070-1
https://tinyurl.com/Niche-070-2
https://tinyurl.com/Niche-070-3
https://tinyurl.com/Niche-070-4
https://tinyurl.com/Niche-070-5
https://tinyurl.com/Niche-070-6
https://tinyurl.com/Niche-070-7
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 069 – BeiGene, Everest, Takeda, Exelixis, PerkinElmer + BioLegend, Prenetics
BeiGene’s oncology machine, China oncology pipelines, COVID costs, two new FDA approvals, $5B life science merger, and Hong Kong joins US SPAC party
Find out more at
https://thenichepod.com
Story References
https://tinyurl.com/Niche-069-1
https://tinyurl.com/Niche-069-2
https://tinyurl.com/Niche-069-3
https://tinyurl.com/Niche-069-4
https://tinyurl.com/Niche-069-5
https://tinyurl.com/Niche-069-6
https://tinyurl.com/Niche-069-7
https://tinyurl.com/Niche-069-8
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 068 – Eli Lilly + ProQR, Sanofi + Kadmon, Lycia, BlueBird + 2seventy, Mammoth
$1.5B deal, $1.9B merger, protein degraders get backing, an old bird has new tricks, and another billion-dollar valuation for CRISPR
Find out more at
https://thenichepod.com
Story References
https://tinyurl.com/Niche-068-1
https://tinyurl.com/Niche-068-2
https://tinyurl.com/Niche-068-3
https://tinyurl.com/Niche-068-4
https://tinyurl.com/Niche-068-5
https://tinyurl.com/Niche-068-6
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 067 – Bonus Interview With Sam Searcy – CEO of CliniStart
This week, I go on vacation and give you a special bonus interview with Sam Searcy, founder and CEO of CliniStart and former NC State Senator
Find out more at
https://thenichepod.com
Story References
https://clinistart.com/
https://www.samsearcy.com/
https://www.linkedin.com/in/samuel-searcy-3462891a4/
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 066 – Cassava, Reify, Hamacyte, Pfizer + Moderna + FDA, Ascendis
The Cassava saga, Reify goes big… too big? Humacyte SPAC, vax news you already know, and a new growth hormone therapy – approved!
Find out more at
https://thenichepod.com
Story References
https://tinyurl.com/Niche-066-1
https://tinyurl.com/Niche-066-2
https://tinyurl.com/Niche-066-3
https://tinyurl.com/Niche-066-4
https://tinyurl.com/Niche-066-5
https://tinyurl.com/Niche-066-6
https://tinyurl.com/Niche-066-7
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 065 – Verily, Athira, Bain, Merck, GSK, Abogen
Alphabet buys, uncertain futures, new biotech funds, HIF-2a, PD-1, and a China Biotech emerges.
Find out more at
https://thenichepod.com
Story References
https://tinyurl.com/Niche-065-1
https://tinyurl.com/Niche-065-2
https://tinyurl.com/Niche-065-3
https://tinyurl.com/Niche-065-4
https://tinyurl.com/Niche-065-5
https://tinyurl.com/Niche-065-6
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
Responses